# S-Venture Capital Dortmund

> S-Venture Capital Dortmund is a VC fund backing Biotechnology and Guides. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Deutsch, Germany
- Total investments: 9
- Last investment: Sep 2010
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.svc-do.de

S-Venture Capital Dortmund is a VC fund in Deutsch focused on Biotechnology and Guides. S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.

## Contacts

5 contacts available for S-Venture Capital Dortmund. Shizune tracks 2 team members at S-Venture Capital Dortmund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/s-capital-dortmund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $3.6M–$9M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 22% |
| Guides | 1 | 11% |
| Genetics | 1 | 11% |
| Software | 1 | 11% |
| Manufacturing | 1 | 11% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 22% |
| Funding Round | 2 | 22% |
| Series A | 1 | 11% |
| Series C | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bernd Meyer | CEO | 0 | https://shizune.co/investors/profile/bernd-meyer |
| Gerhard Steinkamp | Director | 0 | https://shizune.co/investors/profile/gerhard-steinkamp |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Protagen | Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. | $12.7M |  | Sep 07, 2010 |  |
| Protagen | Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. | $5.3M |  | Aug 03, 2009 |  |
| Innolume | Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power. | $9.4M | Series C | Aug 04, 2008 |  |
| Protagen | Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. |  |  | Aug 01, 2008 |  |
| Protagen | Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. | $1.1M |  | Jan 15, 2008 |  |
| Scienion | SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields – from early research to manufacturing. | $4.9M |  | Jul 18, 2006 |  |
| Innolume | Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power. | $9M | Series B | Jun 15, 2006 |  |
| Protagen | Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. | $3.6M | Series B | May 08, 2006 |  |
| COMCO AG | The COMCO security system detects and suppresses internal attacks on corporate networks that previously went undetected, as appropriate protections were not available. |  | Series A | Jul 12, 2005 |  |

9 of 9 investments shown.

## Co-investors
- [KfW](https://shizune.co/investors/profile/kfw) — VC Fund, 4 deals together
- [MIG Capital](https://shizune.co/investors/profile/mig-ag) — VC Fund, 4 deals together
- [NRW.BANK](https://shizune.co/investors/profile/nrw-bank) — VC Fund, 4 deals together
- [Peppermint Holding](https://shizune.co/investors/profile/peppermint-financial-partners) — VC Fund, 3 deals together
- [Applied Ventures](https://shizune.co/investors/profile/applied-ventures) — VC Fund, 1 deal together
- [eCAPITAL ENTREPRENEURIAL PARTNERS](https://shizune.co/investors/profile/ecapital-entrepreneurial-partners-ag) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Germany](https://shizune.co/investors/health-care-vc-funds-germany)
- [Biotech Investors in Germany](https://shizune.co/investors/biotech-investors-germany)
- [Biotech VC Funds in Germany](https://shizune.co/investors/biotech-vc-funds-germany)
- [Biotechnology VC Funds in Germany](https://shizune.co/investors/biotechnology-vc-funds-germany)
- [Medical Device Investors in Germany](https://shizune.co/investors/medical-device-investors-germany)
- [Medical Device VC Funds in Germany](https://shizune.co/investors/medical-device-vc-funds-germany)

## FAQ

### What does S-Venture Capital Dortmund invest in?

S-Venture Capital Dortmund invests primarily in Biotechnology, Guides and Genetics startups, most often at Series B and Funding Round stage. Most of the 9 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is S-Venture Capital Dortmund's check size?

S-Venture Capital Dortmund typically joins rounds of $3.6M–$9M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds S-Venture Capital Dortmund participates in.

### How do I contact S-Venture Capital Dortmund?

Public channels for S-Venture Capital Dortmund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at S-Venture Capital Dortmund?

The team at S-Venture Capital Dortmund includes Bernd Meyer (CEO) and Gerhard Steinkamp (Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co